1
|
Gibson J, Baird T, Pandey S, Tolson C, Coulter C, Eather G, Thomson R. The clinical significance of Mycobacterium triplex. Respir Med 2019; 159:105808. [PMID: 31731086 DOI: 10.1016/j.rmed.2019.105808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2019] [Revised: 09/08/2019] [Accepted: 11/01/2019] [Indexed: 11/19/2022]
Abstract
OBJECTIVES Mycobacterium triplex is a slow-growing nontuberculous mycobacteria (NTM) and is a rare cause of human disease. The pathogenicity, natural history and spectrum of disease is unknown. The aim of this study was to review the clinical features, outcomes and drug susceptibility testing (DST) of all M. triplex isolates in Queensland, Australia to guide management of this rare NTM infection in the future. METHODS This retrospective study included all patients who isolated M. triplex in Queensland, Australia from the 1st January 2000 to 31st December 2016. Clinical information was obtained from medical records to determine the clinical significance of isolates, natural history of disease and treatment outcomes. DST was performed on 15 isolates. RESULTS Forty-three patients (21 male) had positive cultures for M. triplex. Thirty-nine patients had isolates from pulmonary specimens and 17 (43.6%) met the American Thoracic Society criteria for NTM lung disease. Six patients with pulmonary infection received antimicrobial therapy with 5 patients demonstrating treatment success. Four patients had localised extrapulmonary disease and were cured with surgical management ± antimicrobial therapy. DST suggests 93% of isolates are susceptible to macrolides. CONCLUSION This is the largest case series of M. triplex isolates and confirms it is a rare human pathogen. Extrapulmonary disease responded well to surgical management. Treatment of M. triplex pulmonary disease is challenging, and the optimal antimicrobial regimen is unknown. However, the DST data suggests macrolide resistance is rare and macrolides should be included in treatment regimens.
Collapse
Affiliation(s)
- Justine Gibson
- Princess Alexandra Hospital, Brisbane, Queensland, Australia; Metro South Clinical Tuberculosis Service, Brisbane, Queensland, Australia.
| | - Tim Baird
- Sunshine Coast University Hospital, Queensland, Australia
| | - Sushil Pandey
- Queensland Mycobacterium Reference Laboratory (QMRL), Pathology Queensland, Brisbane, Australia
| | - Carla Tolson
- Queensland Mycobacterium Reference Laboratory (QMRL), Pathology Queensland, Brisbane, Australia
| | - Chris Coulter
- Metro South Clinical Tuberculosis Service, Brisbane, Queensland, Australia; Queensland Mycobacterium Reference Laboratory (QMRL), Pathology Queensland, Brisbane, Australia
| | - Geoffrey Eather
- Princess Alexandra Hospital, Brisbane, Queensland, Australia; Metro South Clinical Tuberculosis Service, Brisbane, Queensland, Australia
| | - Rachel Thomson
- Metro South Clinical Tuberculosis Service, Brisbane, Queensland, Australia; University of Queensland, Brisbane, Queensland, Australia; Gallipoli Medical Research Institute, Brisbane, Queensland, Australia; Greenslopes Private Hospital, Brisbane, Queensland, Australia
| |
Collapse
|
2
|
Shirata M, Tamaru A, Marumo S, Fukui M. Mycobacterium triplex pulmonary disease in an immunocompetent host: A case report and literature review. IDCases 2019; 18:e00648. [PMID: 31720222 PMCID: PMC6838927 DOI: 10.1016/j.idcr.2019.e00648] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2019] [Revised: 09/24/2019] [Accepted: 09/24/2019] [Indexed: 11/17/2022] Open
Abstract
The report describes a rare case of pulmonary disease due to M. triplex. The pulmonary lesion was discovered as an incidental finding on chest X-ray. The organism was identified by housekeeping gene sequencing analysis. The patient had a history of tuberculosis & non-tuberculous mycobacterial infection. The patient was treated with antimicrobials and the lesion was cured.
Mycobacterium triplex (M. triplex) is a bacterial species that can cause severe pulmonary diseases. Despite its clinical importance, only a few cases of M. triplex infection have been reported. Here, we present a rare case of pulmonary disease due to M. triplex in an immunocompetent patient who showed abnormal findings on chest X-ray and computed tomography scans. In this patient, the bacterium was identified by DNA sequencing analysis of the 16S rRNA and hsp65 genes. The patient was successfully treated with the appropriate antimicrobial agents. To put this case into the context of the current literature, we also reviewed other case reports of M. triplex infection.
Collapse
Affiliation(s)
- Masahiro Shirata
- Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan
- Corresponding author.
| | - Aki Tamaru
- Division of Microbiology, Bacteriology Section, Osaka Institute of Public Health, 1-3-69 Nakamichi, Higashinari-ku, Osaka 537-0025, Japan
| | - Satoshi Marumo
- Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan
| | - Motonari Fukui
- Respiratory Disease Center, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan
| |
Collapse
|
3
|
Matsuda S, Suzuki S, Morimoto K, Aono A, Nishio K, Asakura T, Sasaki Y, Namkoong H, Nishimura T, Ogata H, Hasegawa N, Kurashima A, Ishii M, Tatsumi K, Mitarai S, Goto H. Mycobacterium triplex pulmonary disease with acquired macrolide resistance in immunocompetent patients. Clin Microbiol Infect 2018; 24:671-672. [PMID: 29309938 DOI: 10.1016/j.cmi.2017.12.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 12/25/2017] [Accepted: 12/26/2017] [Indexed: 11/26/2022]
Affiliation(s)
- S Matsuda
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - S Suzuki
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - K Morimoto
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan; Division of Clinical Research, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
| | - A Aono
- Department of Mycobacterium Reference and Research, The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - K Nishio
- Department of Respiratory Medicine, Kawasaki Municipal Ida Hospital, Kanagawa, Japan
| | - T Asakura
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Y Sasaki
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - H Namkoong
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - T Nishimura
- Health Centre, Keio University, Tokyo, Japan
| | - H Ogata
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - N Hasegawa
- Centre for Infectious Diseases and Infection Control, Keio University School of Medicine, Tokyo, Japan
| | - A Kurashima
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - M Ishii
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - K Tatsumi
- Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - S Mitarai
- Department of Mycobacterium Reference and Research, The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - H Goto
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| |
Collapse
|
4
|
Steffani-Vallejo JL, Brunck ME, Acosta-Cruz EY, Montiel R, Barona-Gómez F. Genomic insights into Mycobacterium simiae human colonization. Stand Genomic Sci 2018; 13:1. [PMID: 29340007 PMCID: PMC5759803 DOI: 10.1186/s40793-017-0291-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Accepted: 11/24/2017] [Indexed: 12/24/2022] Open
Abstract
Mycobacterium simiae (Karassova V, Weissfeiler J, Kraszanay E, Acta Microbiol Acad Sci Hung 12:275-82, 1965) is a slow-growing nontuberculous Mycobacterium species found in environmental niches, and recently evidenced as an opportunistic Human pathogen. We report here the genome of a clinical isolate of M. simiae (MsiGto) obtained from a patient in Guanajuato, Mexico. With a size of 6,684,413 bp, the genomic sequence of strain MsiGto is the largest of the three M. simiae genomes reported to date. Gene prediction revealed 6409 CDSs in total, including 6354 protein-coding genes and 52 RNA genes. Comparative genomic analysis identified shared features between strain MsiGto and the other two reported M. simiae genomes, as well as unique genes. Our data reveals that M. simiae MsiGto harbors virulence-related genes, such as arcD, ESAT-6, and those belonging to the antigen 85 complex and mce clusters, which may explain its successful transition to the human host. We expect the genome information of strain MsiGto will provide a better understanding of infective mechanisms and virulence of this emergent pathogen.
Collapse
Affiliation(s)
- José L. Steffani-Vallejo
- Evolution of Metabolic Diversity Laboratory, Unidad de Genómica Avanzada (Langebio), Cinvestav-IPN, Irapuato, Mexico
| | - Marion E. Brunck
- Centro de Biotecnología FEMSA, Escuela de Ingeniería y Ciencias, Tecnológico de Monterrey, Monterrey, Mexico
| | - Erika Y. Acosta-Cruz
- Evolution of Metabolic Diversity Laboratory, Unidad de Genómica Avanzada (Langebio), Cinvestav-IPN, Irapuato, Mexico
- Paleogenomics Laboratory, Unidad de Genómica Avanzada (Langebio), Cinvestav-IPN, Irapuato, Mexico
- Present address: Laboratorio de Biología Molecular, Facultad de Ciencias Químicas, Universidad Autónoma de Coahuila, Saltillo, Mexico
| | - Rafael Montiel
- Paleogenomics Laboratory, Unidad de Genómica Avanzada (Langebio), Cinvestav-IPN, Irapuato, Mexico
| | - Francisco Barona-Gómez
- Evolution of Metabolic Diversity Laboratory, Unidad de Genómica Avanzada (Langebio), Cinvestav-IPN, Irapuato, Mexico
| |
Collapse
|